SCHEMBL6350461

SCHEMBL6350461

Cc1ccc(S(=O)(=O)N2CCN(c3ncccn3)CC2)cc1CC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
ALDH1A1 P00352 4/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 5/20 0.53
MEN1 O00255 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPK1 P28482 2/20 0.52
KDM4E B2RXH2 3/20 0.52
HTT P42858 2/20 0.52
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
HDAC3 O15379 1/20 0.48
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC2 Q92769 1/20 0.48
HDAC10 Q969S8 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5748050 0.88 PTPN11 (0.47) ALDH1A1KMT2AMEN1KDM4EHTT
SCHEMBL5749490 0.88 HDAC3 (0.45) SMN1; SMN2ALDH1A1L3MBTL1RAB9AKMT2A
SCHEMBL5747437 0.88 HDAC3 (0.47) SMN1; SMN2ALDH1A1L3MBTL1RAB9AKMT2A
SCHEMBL5799838 0.88 PKM (0.47) SMN1; SMN2ALDH1A1L3MBTL1RAB9AKMT2A
SCHEMBL5745816 0.86 LMNA (0.45) ALDH1A1KMT2AMEN1TDP1KDM4E
SCHEMBL5747078 0.85 MEN1 (0.66) SMN1; SMN2ALDH1A1KMT2AMEN1GAA
SCHEMBL5749155 0.83 TSHR (0.47) ALDH1A1L3MBTL1KMT2AMEN1TDP1
SCHEMBL5770088 0.83 HSD11B1 (0.66) HSD11B1
SCHEMBL5806971 0.80 HSD11B1 (0.63) HSD11B1
SCHEMBL5748016 0.80 MEN1 (0.46) SMN1; SMN2ALDH1A1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD SMN1; SMN2 2173/4885ALDH1A1 883/4885L3MBTL1 4277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.